Phacilitate Leaders World

Speakers

Loading
Frank  Tufaro

Frank Tufaro

CEO, DNAtrix Therapeutics

Frank Tufaro has extensive experience with the founding, financing, and operation of biotechnology firms. Prior to DNAtrix, Frank was part of the founding team of NeuroVir, a Vancouver-based biotech company with a mission to develop herpes-simplex virus oncolytic vectors for treating cancer. Frank was instrumental in raising venture financing that established NeuroVir as the major player in the field of viral oncology and led to its acquisition by MediGene. Frank also co-founded Nurel Therapeutics, a gene therapy company acquired by Diamyd Medical AB, and Allera Health Products. Previously, Frank was a Professor of Microbiology at the University of British Columbia, wherein his laboratory worked on herpes simplex virus and gene therapy for cancer. Frank received his BSc in Cell and Molecular Biology, a PhD in Developmental Biology from McGill University and was a postdoctoral fellow with Dr. Steve McKnight, at the Fred Hutchinson Cancer Center and the Carnegie Institution of Science. 

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK